IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.851
EU - Europa 2.175
AS - Asia 2.087
SA - Sud America 30
Continente sconosciuto - Info sul continente non disponibili 24
AF - Africa 20
OC - Oceania 15
Totale 9.202
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.659
SG - Singapore 1.358
IT - Italia 1.169
CN - Cina 452
SE - Svezia 385
GB - Regno Unito 290
CA - Canada 180
IN - India 99
DE - Germania 76
NL - Olanda 45
RO - Romania 34
FR - Francia 31
HK - Hong Kong 29
FI - Finlandia 25
PK - Pakistan 23
RU - Federazione Russa 23
EU - Europa 22
JO - Giordania 21
IR - Iran 19
ES - Italia 16
UA - Ucraina 16
ID - Indonesia 12
SA - Arabia Saudita 12
AT - Austria 11
AU - Australia 11
BR - Brasile 11
CZ - Repubblica Ceca 11
JP - Giappone 10
CL - Cile 9
KR - Corea 9
MX - Messico 8
PT - Portogallo 8
AE - Emirati Arabi Uniti 7
EG - Egitto 7
IE - Irlanda 7
LT - Lituania 7
EE - Estonia 6
MY - Malesia 5
CY - Cipro 4
NZ - Nuova Zelanda 4
TW - Taiwan 4
ZA - Sudafrica 4
BD - Bangladesh 3
BG - Bulgaria 3
CH - Svizzera 3
ET - Etiopia 3
IL - Israele 3
LB - Libano 3
LK - Sri Lanka 3
MA - Marocco 3
NG - Nigeria 3
PE - Perù 3
PH - Filippine 3
TR - Turchia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CO - Colombia 2
EC - Ecuador 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
PL - Polonia 2
PS - Palestinian Territory 2
VN - Vietnam 2
AR - Argentina 1
BO - Bolivia 1
DK - Danimarca 1
IQ - Iraq 1
UY - Uruguay 1
Totale 9.202
Salva come PNG Salva come JPEG
Città #
Chandler 906
Singapore 426
Santa Clara 420
Milan 385
Lawrence 383
Princeton 383
Chicago 255
London 237
Wilmington 224
Ottawa 163
Ashburn 153
Catanzaro 153
Des Moines 111
Beijing 72
Boardman 60
Shanghai 48
Guangzhou 41
Rome 40
Pune 37
Norwalk 32
Redwood City 30
Redmond 28
Helsinki 25
Los Angeles 25
Hong Kong 23
Naples 23
Munich 22
Parma 19
San Nicola Manfredi 16
New York 15
West Jordan 14
Amman 13
Horia 13
Mountain View 13
Palermo 12
Timisoara 12
Vallefiorita 12
Augusta 11
Cosenza 11
Hanover 11
Reggio Calabria 11
Washington 11
Delhi 10
Madrid 10
Zhengzhou 10
Aversa 9
Jiaxing 9
Shenzhen 9
Ahmedabad 8
Cicciano 8
Council Bluffs 8
Ercolano 8
Irbid 8
Olomouc 8
Santo Stefano di Rogliano 8
Xi'an 8
Bari 7
Kaunas 7
Seattle 7
Settingiano 7
Spezzano della Sila 7
Afragola 6
Amsterdam 6
Catania 6
Frankfurt am Main 6
Melito di Porto Salvo 6
Nanjing 6
Riyadh 6
San Francisco 6
Sezze 6
Toronto 6
Wuxi 6
Ann Arbor 5
Cardiff 5
Hefei 5
Hyderabad 5
Islamabad 5
Jinhua 5
Leawood 5
Lucknow 5
Meppel 5
Moscow 5
Oristano 5
Puteaux 5
Quanzhou 5
Sacramento 5
Seoul 5
Siano 5
Taranto 5
Wuhan 5
Andover 4
Brescia 4
Buffalo 4
Caserta 4
Chennai 4
Clearwater 4
Decollatura 4
Dongyang 4
Hebei 4
Jeddah 4
Totale 5.251
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 309
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 73
miR-22 suppresses DNA ligase III addiction in multiple myeloma 73
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 60
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 58
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 53
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 52
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 51
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 51
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 50
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 49
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 49
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 48
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 47
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 47
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 46
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 46
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 45
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 45
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 45
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 44
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 44
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 43
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 43
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 42
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 41
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 41
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 41
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 40
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 39
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 39
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 38
Modulation of Exosomal microRNA in patients with severe Aortic Stenosis after Transcatheter Aortic Valve Implantation (TAVI) 38
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 38
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 38
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 38
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 38
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 37
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 37
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 36
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 36
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 35
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 35
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 35
Mir-34: a new weapon against cancer? 35
Mir-221/222 are promising targets for innovative anticancer therapy 35
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 35
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 35
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 35
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 35
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 35
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 34
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 34
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 34
Mmrf-commpass data integration and analysis for identifying prognostic markers 34
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 34
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 33
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 33
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 33
Transcriptional regulation of the mismatch repair gene hMLH1 33
Liposomes containing zoledronic acid: A new opportunity against cancer 33
[Magnesium salts in the treatment of ventricular tachycardia]. FT I sali di magnesio nel trattamento della tachicardia ventricolare. 33
Serum Programmed death-ligand 1 (PD-L1) as biomarker or response for anti-PD-L1 immunotherapy 33
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 32
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth 32
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 32
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma 32
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 32
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 32
Identification by differential display of cDNA sequences regulated during hematopoietic differentiation and in leukemias 32
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 32
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 32
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 32
Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues 31
UN1, a murine monoclonal antibody recognizing a novel human thymic antigen 31
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 31
miR-221/222 inhibitors for the treatment of multiple myeloma 31
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 31
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 31
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. 30
Hereditary nonpolyposis colon cancer results from heritable defects in the MLH1, MSH2, PMS1 and PMS2 genes, which encode proteins involved in the mismatch repair process. In this work we report the identification of two novel germline mutations in the MLH1 gene from two unrelated HNPCC families. The two affected families do not fulfill the Amsterdam criteria. In family 1 we found a missense S93G mutation, which lies in a MLH1 domain critical for its MMR functions. In family 2 we found a two nucleotide insertion (AG) in position 523 from the AUG which determines an early stop codon at position 606 (codon 203). In both families the mutant alleles cosegregate with the cancer phenotype. 30
Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment 30
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 30
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 30
A clinically relevant SCID-hu in vivo model of human multiple myeloma 30
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 30
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 30
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 30
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 30
Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: Experimental models and translational issues 29
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 29
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 29
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 29
HLA class I, NKG2D, anda natural cytotoxicity receptors regulate multiple myeloma cell recogntion by natural killer cells 29
CD69 expression on primitive progenitor cells and hematopoietic malignancies 29
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 29
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 29
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 29
Integration of DNA Microarray with Clinical and Genomic Data 29
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 28
Totale 4.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020197 0 0 0 0 0 0 0 0 0 0 45 152
2020/2021516 51 20 12 23 63 53 33 26 73 82 65 15
2021/20221.151 27 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20253.111 615 274 203 134 251 564 126 163 510 266 5 0
Totale 9.523